Cargando…

The Potency of Platelet-Rich Plasma for Chronic Low Back Pain: A Systematic Review and Meta-analysis of Randomized Controlled Trial

Low back pain is one of the leading causes of disability in the world. Regenerative medicine can be one of the novel treatment breakthroughs in patients with low back pain, yet its use is still debatable. We performed a systematic evaluation and meta-analysis to determine the efficacy of platelet-ri...

Descripción completa

Detalles Bibliográficos
Autores principales: Singjie, Leonard Christianto, Kusuma, Samuel Andi, Saleh, Ifran, Kholinne, Erica
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Korean Society of Spine Surgery 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10460651/
https://www.ncbi.nlm.nih.gov/pubmed/37183000
http://dx.doi.org/10.31616/asj.2022.0209
Descripción
Sumario:Low back pain is one of the leading causes of disability in the world. Regenerative medicine can be one of the novel treatment breakthroughs in patients with low back pain, yet its use is still debatable. We performed a systematic evaluation and meta-analysis to determine the efficacy of platelet-rich plasma (PRP) treatment for patients with chronic low back pain. Comprehensive database searches were performed in four databases. This study was conducted and reported based on the Preferred Reporting Items for Systematic Reviews and Meta-analyses Guideline and registered to PROSPERO. We included and examined randomized controlled trials that looked into research employing PRP for patients with chronic low back pain. Outcomes of interest include clinical enhancement of pain, which is demonstrated in pain scores. Three studies were included comprising 138 patients with chronic low back pain. After 1, 3, and 6 months after injection, there was a substantial reduction in the pain score difference between the PRP and control groups, demonstrating PRP’s superiority over the control group in the treatment of chronic low back pain. PRP injection significantly enhances chronic low back pain in the first, third, and sixth months after injection compared to controls.